ES2329689T3 - Composiciones y procedimientos para el diagnostico de tumores. - Google Patents

Composiciones y procedimientos para el diagnostico de tumores. Download PDF

Info

Publication number
ES2329689T3
ES2329689T3 ES05019847T ES05019847T ES2329689T3 ES 2329689 T3 ES2329689 T3 ES 2329689T3 ES 05019847 T ES05019847 T ES 05019847T ES 05019847 T ES05019847 T ES 05019847T ES 2329689 T3 ES2329689 T3 ES 2329689T3
Authority
ES
Spain
Prior art keywords
amino acid
acid sequence
seq
identity
signal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05019847T
Other languages
English (en)
Inventor
David Botstein
Audrey Goddard
Austin L Gurney
Margaret Ann Roy
Colin K Watanabe
William I Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2329689T3 publication Critical patent/ES2329689T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Anticuerpo aislado que se une a un polipéptido PRO3567, para su uso en un procedimiento de diagnóstico de cáncer de colon practicado en el cuerpo humano o animal, en el que dicho PRO3567 es una secuencia de aminoácido a) que tiene al menos el 99% de identidad en la secuencia de aminoácidos mostrada en la Figura 2 (SEC ID Nº: 27); b) que da una valoración al menos el 99% de positivos cuando se compara con una secuencia de aminoácidos seleccionada mostrada en la Figura 2 (SEC ID Nº: 27); c) que tiene al menos el 99% de identidad en la secuencia de aminoácidos con una secuencia de aminoácidos codificada por la secuencia codificante de longitud completa del ADN depositado con el número de entrada en la ATCC 203662; d) que tiene al menos el 99% de identidad en la secuencia de aminoácidos con el polipéptido mostrado en la Figura 2 (SEC ID Nº: 27), que carece de su péptido señal asociado; e) que tiene al menos el 99% de identidad en la secuencia de aminoácidos con un dominio extracelular del polipéptido mostrado en la Figura 2 (SEC ID Nº: 27), con su péptido señal asociado; o f) que tiene al menos el 99% de identidad en la secuencia de aminoácidos con un dominio extracelular del polipéptido mostrado en la Figura 2 (SEC ID Nº: 27), que carece de su péptido señal asociado.
ES05019847T 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores. Expired - Lifetime ES2329689T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
US16250699P 1999-10-29 1999-10-29
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
ES2329689T3 true ES2329689T3 (es) 2009-11-30

Family

ID=29215742

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05019849T Expired - Lifetime ES2324876T3 (es) 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores.
ES05019847T Expired - Lifetime ES2329689T3 (es) 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES05019849T Expired - Lifetime ES2324876T3 (es) 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores.

Country Status (9)

Country Link
EP (6) EP1642907B1 (es)
JP (7) JP2003525585A (es)
KR (5) KR100543857B1 (es)
AT (2) ATE439431T1 (es)
AU (4) AU773055C (es)
CA (1) CA2367334A1 (es)
DE (2) DE69940681D1 (es)
ES (2) ES2324876T3 (es)
WO (1) WO2000053750A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008284A2 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6914130B2 (en) * 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1140120A4 (en) * 1998-12-23 2003-05-07 Human Genome Sciences Inc HUMAN BRAINIAC-5
EP1224201A4 (en) * 1999-10-29 2005-03-02 Human Genome Sciences Inc 32 HUMAN SECRETED PROTEINS
AU2001241080A1 (en) * 2000-03-10 2001-09-17 Toshio Kitamura Mouse adipocyte-origin genes
US20020123475A1 (en) * 2000-06-30 2002-09-05 Leiby Kevin R. 32626, a novel human UDP-glycosyltransferase and uses thereof
EP1399564A2 (en) * 2001-02-16 2004-03-24 Incyte Genomics, Inc. Drug metabolizing enzymes
GB0110273D0 (en) * 2001-04-26 2001-06-20 Inpharmatica Ltd Novel proteins
JP2004147542A (ja) * 2002-10-30 2004-05-27 National Institute Of Advanced Industrial & Technology 糖転移酵素及びそれをコードする核酸、並びに該核酸を用いた癌組織の検出方法
AU2006223579A1 (en) * 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP2009131151A (ja) * 2006-02-28 2009-06-18 Osaka Univ ＰＩＬＲαと結合するポリペプチド、およびそれをコードするポリヌクレオチド、並びにその利用
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
WO2015010615A1 (zh) * 2013-07-23 2015-01-29 四川大学华西医院 一种重组trail蛋白及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976790A (en) * 1992-03-04 1999-11-02 The Regents Of The University Of California Comparative Genomic Hybridization (CGH)
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
JP3399948B2 (ja) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ Ｐ９０抗体またはプローブを用いた前癌細胞または癌細胞の検出方法
CA2296815A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. 64 human secreted proteins
ATE440951T1 (de) * 1997-12-17 2009-09-15 Serono Genetics Inst Sa Verlängerte cdns, die für sekretierte proteine kodieren
JP2002508167A (ja) * 1997-12-18 2002-03-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １１０個のヒト分泌タンパク質
CA2314379A1 (en) * 1997-12-18 1999-06-24 Human Genome Sciences, Inc. Human dendriac and brainiac-3
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
EP1080194A2 (en) * 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
EP1097199A4 (en) * 1998-07-15 2005-02-23 Human Genome Sciences Inc 71 HUMAN SECRETED PROTEINS
AU1181900A (en) * 1998-11-17 2000-06-05 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
CA2348757A1 (en) * 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1140120A4 (en) * 1998-12-23 2003-05-07 Human Genome Sciences Inc HUMAN BRAINIAC-5
EP1147182A2 (en) * 1999-01-12 2001-10-24 ZymoGenetics, Inc. Human beta-1,3-galactosyltransferase homolog, znssp6
KR100468976B1 (ko) * 1999-02-10 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
EP1197556A4 (en) * 1999-06-29 2003-01-22 Kyowa Hakko Kogyo Kk USEFUL POLYPEPTIDES
EP1194549A2 (en) * 1999-07-02 2002-04-10 Chiron Corporation Human genes and gene expression products
JP2002017375A (ja) * 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 全長ｃＤＮＡ合成用プライマー、およびその用途
EP1130094A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
EP1248798A2 (en) * 1999-08-18 2002-10-16 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Human dna sequences
EP1212354A2 (en) * 1999-09-10 2002-06-12 Corixa Corporation Ovarian tumor sequences and methods of use therefor
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides

Also Published As

Publication number Publication date
AU2004201760B2 (en) 2007-07-19
JP2003525585A (ja) 2003-09-02
JP2009039097A (ja) 2009-02-26
EP1642906A2 (en) 2006-04-05
AU773055B2 (en) 2004-05-13
JP2003274977A (ja) 2003-09-30
JP2003274980A (ja) 2003-09-30
EP1642967A2 (en) 2006-04-05
WO2000053750A1 (en) 2000-09-14
EP1642906A3 (en) 2006-07-26
EP1642967A3 (en) 2006-07-26
AU2004201759A1 (en) 2004-05-20
AU773055C (en) 2004-12-02
CA2367334A1 (en) 2000-09-14
KR100543857B1 (ko) 2006-01-23
EP1642907B1 (en) 2009-04-01
EP1634892A2 (en) 2006-03-15
EP1159422A1 (en) 2001-12-05
ATE439431T1 (de) 2009-08-15
KR100566839B1 (ko) 2006-04-03
EP1642968A3 (en) 2006-06-21
AU2004201769A1 (en) 2004-05-27
EP1642907A3 (en) 2006-06-21
KR20040073588A (ko) 2004-08-19
DE69941273D1 (de) 2009-09-24
JP2009000114A (ja) 2009-01-08
EP1634892A3 (en) 2006-06-21
AU2004201769B2 (en) 2007-07-19
EP1642907A2 (en) 2006-04-05
ES2324876T3 (es) 2009-08-18
KR20040077790A (ko) 2004-09-06
EP1642968A2 (en) 2006-04-05
AU2004201759B2 (en) 2007-07-19
KR20050004773A (ko) 2005-01-12
DE69940681D1 (de) 2009-05-14
EP1642968B1 (en) 2009-08-12
KR20020008123A (ko) 2002-01-29
ATE427319T1 (de) 2009-04-15
AU2004201760A1 (en) 2004-05-20
KR100473551B1 (en) 2005-03-14
JP2003274979A (ja) 2003-09-30
AU3107700A (en) 2000-09-28
KR100473550B1 (en) 2005-03-15
KR100517848B1 (en) 2005-09-30
KR20040088077A (ko) 2004-10-15
JP2003274978A (ja) 2003-09-30

Similar Documents

Publication Publication Date Title
ES2329689T3 (es) Composiciones y procedimientos para el diagnostico de tumores.
ES2332916T3 (es) Composiciones y metodo para el tratamiento de tumores.
WO2001057182A3 (en) Nucleic acids, proteins, and antibodies
ATE427354T1 (de) Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden
WO2000055180A3 (en) Human lung cancer associated gene sequences and polypeptides
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
ECSP024210A (es) Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
WO2001059063A3 (en) Nucleic acids, proteins, and antibodies
WO2001055317A8 (en) Nucleic acids, proteins, and antibodies
BG101024A (bg) Моноклонално антитяло срещу сd44v6
ES2085993T3 (es) Proteina asociada a la pancreatitis aguda, medios para el diagnostico de la pancreatitis aguda.
WO1999027098A3 (en) A-33 related antigens and their pharmacological uses
ATE547523T1 (de) Vegfr-varianten und deren verwendung bei der diagnose und behandlung von mit schwangerschaft assoziierten medizinischen leiden
ATE299182T1 (de) Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie
BR9510067A (pt) Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo
DK0979235T3 (da) Isoleret nukleinsyremolekyle, der koder for tumorafstödende antigenprecursors MAGE-C1 og MAGE-C2, og anvendelser deraf
TR200102655T2 (tr) Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen.
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
TR200003345T2 (tr) Moraxella Catarrhalıs'in bileşikleri
WO2001055313A3 (en) Nucleic acids, proteins, and antibodies
ATE440110T1 (de) Zusammensetzungen und verfahren zur behandlung der polyzystischen nierenkrankheit
ATE321863T1 (de) Diagnostischer test für von pferdearthritisvirus verursachte krankheiten
DE69828986D1 (de) Men1, mit typ 1 multipler endokriner neoplasie assoziiertes gen, meninpolypeptide und deren verwendungen